Clinically significant macular edema; hard soapy exudates of retina
Item
1. patients diagnosed with csme (clinically significant macular edema) with hard exudates within 1500 micrometer from foveal center
boolean
C0730284 (UMLS CUI [1])
C2029279 (UMLS CUI [2])
best corrected visual acuity
Item
2. those who have a bcva (best corrected visual acuity) of study eye between 0.06(20/320) and 0.5(20/40)
boolean
C1690532 (UMLS CUI [1])
Macular grid.center point thickness
Item
3. those who have a central macular thickness on oct over 300 micrometer
boolean
C2735398 (UMLS CUI [1])
hard soapy exudates of retina
Item
4. if both eyes are eligible, eye having more hard exudates is selected (contralateral eye should be treated with corticosteroid other than ozurdex or focal laser photocoagulation, anti-vegf (vascular endothelial growth factor) injection is not allowed in contralateral eye)
boolean
C2029279 (UMLS CUI [1])
Clinically significant macular edema; Without; hard soapy exudates of retina
Item
1. those who have csme without hard exudates
boolean
C0730284 (UMLS CUI [1])
C0332288 (UMLS CUI [2])
C2029279 (UMLS CUI [3])
Macular retinal edema
Item
2. those who have macular edema not related with diabetic retinopathy (e.g. amd (age-related macular degeneration), uveitis, retinal vein occlusion and untreated malignant hypertension)
boolean
C0271051 (UMLS CUI [1])
surgery intraocular
Item
3. those who have a history of intraocular surgery (e.g. cataract surgery) within 3 months
boolean
C0038894 (UMLS CUI [1,1])
C3282905 (UMLS CUI [1,2])
visual acuity; eye
Item
4. those who have a visual acuity of contralateral eye less than 0.1 (10/100)
boolean
C0042812 (UMLS CUI [1])
C0015392 (UMLS CUI [2])
Laser treatment; Retinal macula
Item
5. those who received focal laser treatment on macula within 3 months
boolean
C0850168 (UMLS CUI [1])
C0450295 (UMLS CUI [2])
Intravitreal Injections
Item
6. those who had intravitreal anti-vegf agent injection within 3 months
boolean
C1554888 (UMLS CUI [1])
triamcinolone; Intravitreal Injections
Item
7. those who had intravitreal triamcinolone injection within 6 months
boolean
C0040864 (UMLS CUI [1])
C1554888 (UMLS CUI [2])
Disease ophthalmologic
Item
8. those who have other ophthalmologic disease affecting visual acuity (e.g. central corneal opacity, cataract change at lens center)
boolean
C0012634 (UMLS CUI [1,1])
C0205481 (UMLS CUI [1,2])
Systemic disease
Item
9. those who have severe systemic disease (e.g. uncontrolled dm, hypertension, cardiovascular disease, cerebrovascular disease)
boolean
C0442893 (UMLS CUI [1])
informed consent
Item
10. those who refuse to submit written consent
boolean
C0021430 (UMLS CUI [1])
clinical study; cooperation
Item
11. those who cannot understand the contents of the clinical study and cooperate in the clinical trial
boolean
C0008972 (UMLS CUI [1])
C0392337 (UMLS CUI [2])
pregnant; Lactating
Item
12. those who are pregnant or lactating women
boolean
C0549206 (UMLS CUI [1])
C2828358 (UMLS CUI [2])
Vitrectomy
Item
13. those who have a history of vitrectomy
boolean
C0042903 (UMLS CUI [1])
immunosuppressive agent; treatment systemic
Item
14. those who require systemic corticosteroid or immunosuppressive agent treatment
boolean
C0021081 (UMLS CUI [1])
C0001617 (UMLS CUI [2])
C0087111 (UMLS CUI [3,1])
C0205373 (UMLS CUI [3,2])
ozurdex; prohibition
Item
15. those who are banned from using ozurdex
boolean
C2702456 (UMLS CUI [1])
C0683610 (UMLS CUI [2])
Eye Infections
Item
ocular infection or periocular infection
boolean
C0015403 (UMLS CUI [1])
advanced; glaucoma
Item
advanced glaucoma
boolean
C0205179 (UMLS CUI [1])
C0017601 (UMLS CUI [2])
hypersensitivity; dexamethasone
Item
hypersensitivity to dexamethasone or other component of ozurdex
boolean
C0020517 (UMLS CUI [1])
C0011777 (UMLS CUI [2])
Aphakia
Item
posterior lens capsule rupture or aphakia
boolean
C0003534 (UMLS CUI [1])
Posterior capsule rupture; Anterior chamber lens
Item
anterior chamber intraocular lens or posterior capsule rupture
boolean
C1535895 (UMLS CUI [1])
C0441281 (UMLS CUI [2])